NewsRoom Articles - Page 3 of 154 - PsychedelicNewsWire (PNW)

WednesdayMar 05, 2025 10:00 am

Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk

If you are considering using psychedelics in a non-clinical setting, you might want to hold off for a while. A recently published study has found that individuals who have bad psychedelic trips have a much higher risk of dying within 5 years. Doctor Daniel Myran, a researcher and preventive medicine specialist based at Ontario’s University of Ottawa, was the lead author of that study. He revealed that he was intrigued by all the hype about the mental health benefits of psychedelics but wondered about the real-world experiences of individuals who use these hallucinogens outside a clinical setting. For their study,…

MondayMar 03, 2025 10:00 am

Groups of Military Veterans Urge Congress to Expedite Research on Psychedelics

The U.S. Veterans Affairs Department has been urged by major VSOs (Veterans Service Organizations) to keep looking into psychedelic therapy and other alternative therapies, such as medical marijuana, if these treatments can be proved to be effective. One leading group told Congress that a major stumbling block to the exploration of these novel treatments is the classification of these substances under Schedule 1 of the federal Controlled Substances Act. These views were expressed during a joint hearing of the Senate and House VA committees early this week. The legislators received testimony from various VSOs, and a leading concern across all…

WednesdayFeb 26, 2025 10:00 am

Why Guilt, Shame During Psychedelic Trips Could Actually Be Positive

Interest in psychedelics and their therapeutic potential has grown in recent years, and plenty of studies have been conducted or are currently underway to understand how exactly these substances exert the effects they have. One recent study focused on why some people report experiencing difficult emotions, such as guilt and shame, during their psychedelic sessions and what impact those feelings have on their wellbeing in the days, weeks and months after psychedelic use. The findings of this research were published in the Journal of Psychoactive Drugs. The team found that it was very common for people to experience guilt and…

MondayFeb 24, 2025 10:00 am

Why Funding Isn’t All That Web3 Startups Need

In the world of startups, funding is often seen as the biggest hurdle that many have to jump. Many believe that once a company secures financial backing, success will follow. However, for Web3 startups, funding is just the beginning. Unlike traditional Web2 businesses, Web3 companies face unique challenges, including regulatory issues, security concerns, community building, and the need for strategic partnerships. Without these elements, even well-funded Web3 startups may struggle to succeed. Launching a Web3 startup requires more than just building a product; it demands a clear go-to-market (GTM) strategy for success. Traditional Web2 businesses rely on paid ads and…

MondayFeb 24, 2025 10:00 am

Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use

A pair of bills filed in the Washington State legislature seeks to legalize psychedelics, particularly psilocin and psilocybin, for medicinal purposes in clinical settings. One bill was filed in the state senate while the other was filed in the assembly. Both bills seek to legalize these hallucinogens for adults aged 21 or older. Alex Ramel, a state Representative who co-sponsored the house bill (HB 1433), says he has tracked some research on the subject and it is clear that the combination of talk therapy and psychedelics administered in a medical setting can be a powerful way to treat individuals with…

WednesdayFeb 19, 2025 10:00 am

Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges

With the existing treatments for mental health issues like PTSD, treatment-resistant depression and suicidal thoughts having limited, if any, beneficial effect, U.S. veterans have decided to take matters into their own hands and are helping one another to explore DIY approaches to using psychedelics to find relief from their symptoms. Lena Ramsay, who lives in rural Maine, is one such veteran. During her tour in Afghanistan, she suffered a broken vertebra, shattered an ankle and suffered a TBI (traumatic brain injury). VA doctors gave her antidepressants, sleep medication, sedatives and pain medication to help with the different health challenges she…

TuesdayFeb 18, 2025 10:00 am

New Study Shows Ibogaine Can Be Made Without Using Plant Matter

In a study that was featured in Nature Chemistry, researchers at UC Davis have shown that it is possible to manufacture the psychedelic ibogaine without having to harvest tons of the plant in which this substance occurs naturally. Scientists have long had an interest in studying how ibogaine can be leveraged in mental health care. However, the need to harvest enormous amounts of the plant in Africa known to have this substance has presented the research community with a huge challenge. The recent success by the UC Davis team presents a welcome solution to this hurdle. The team led by…

WednesdayFeb 12, 2025 10:00 am

Reports Reveal New York Magazine, Prohibitionists Collaborated to Create Series Against MDMA Therapy

As the psychedelics industry is still reeling from the FDA’s rejection of an application by Lykos Therapeutics seeking approval of MDMA-assisted therapy as a treatment for PTSD, it has emerged that there were concerted efforts to conduct a smear campaign against the possibility of MDMA being approved as a medicine. In a story carried by The New York Post last week, it was revealed that Psymposia, a group that is opposed to the legalization of psychedelics, conducted a protracted campaign to defeat efforts aimed at having MDMA legalized as a therapy for post-traumatic stress disorder. The NYT story highlighted how…

MondayFeb 10, 2025 10:00 am

Cleveland Clinic Researchers to Test Novel Psychedelic Targeting Postpartum Depression

A team of researchers at Cleveland Clinic plans to conduct a clinical trial to test a proprietary psychedelic aimed at treating postpartum depression. This serious condition affects approximately 1 in 7 women after giving birth. The Phase 2 trial centers on RE104, a formulation that is similar to psilocybin. It is designed to be administered subcutaneously via an injection and the patient requires just one dose of this treatment. It is hoped that this treatment will address the clinical needs of new mothers afflicted by PPD and experience symptoms like sleep disturbances, chronically low mood, feelings of guilt or inadequacy,…

WednesdayFeb 05, 2025 10:00 am

Positive Clinical Trial Data Causes Psychedelic Biopharma Company’s Shares to Nearly Double

A small Ireland-based firm, GH Research, has announced positive results from a small trial it conducted to treat treatment-resistant depression. The results from this trial revealed that their inhalable version of mebufotenin was effective and fast in delivering clinically significant improvements in the patients selected for the study. Mebufotenin is molecularly similar to psilocybin and occurs in some psychedelic mushrooms. The shares of the company jumped nearly 100% upon the release of this news. The results of the trial were released on Monday, Jan. 3 and the trial involved 81 participants. The subjects all suffered from treatment-resistant depression, and evaluations…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000